ClinicalTrials.Veeva

Menu

A Study to Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers

B

Boryung

Status and phase

Completed
Phase 1

Conditions

Essential Hypertension

Treatments

Drug: Fimasartan
Drug: Atorvastatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00991705
A657-BR-CT-109

Details and patient eligibility

About

The purpose of this study is to evaluate the effect of atorvastatin on the pharmacokinetics of fimasartan.

Enrollment

28 patients

Sex

Male

Ages

20 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • age: 20 - 45 years
  • sex: male
  • body weight: greater than 55 kg
  • written informed consent

Exclusion criteria

  • known allergy to Fimasartan and atorvastatin
  • existing cardiac or hematological diseases
  • existing hepatic and renal diseases
  • existing gastrointestinal diseases
  • acute or chronic diseases which could affect drug absorption or metabolism history of any serious psychological disorder
  • positive drug or alcohol screening
  • smokers of 10 or more cigarettes per day 3 month ago
  • participation in a clinical trial during the last 2 months prior to the start of the study

Trial design

28 participants in 2 patient groups

Group B
Other group
Description:
Atorvastatin (7 days) → Fimasartan + Atorvastatin (7 days)
Treatment:
Drug: Atorvastatin
Drug: Fimasartan
Group A
Other group
Description:
Fimasartan (7 days) → Fimasartan + Atorvastatin (7 days)
Treatment:
Drug: Atorvastatin
Drug: Fimasartan

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems